title: Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients.
abstract: BACKGROUND
  Treatment of acute hepatitis C (HCV) in HIV-infected patients has been poorly addressed.
  
  
  OBJECTIVE
  To evaluate the efficacy and tolerability of a 24 week course of pegylated interferon alfa 2a (PegIFNalpha2a) and ribavirin for the treatment of acute HCV infection in HIV-infected patients.
  
  
  METHODS
  This was a prospective pilot study of 25 consecutive HIV-infected men with acute HCV infection defined by documented HCV seroconversion to anti-HCV positive antibody and positive qualitative HCV RNA measurement. Patients with detectable HCV RNA (> 50 IU/ml) 12 weeks after diagnosis were offered treatment with PegIFNalpha2a (180 microg/week) and ribavirin (800 mg/day) for 24 weeks. Sustained virological response was defined by a negative qualitative HCV RNA measurement 24 weeks after the end of treatment.
  
  
  RESULTS
  At baseline, 23 patients were taking HAART, 23 patients had HIV RNA < 200 copies/ml and a median CD4 count of 345 cells/microl. Only one patient, with genotype 3 HCV, had a spontaneous clearance of HCV RNA. Of the remaining 24 patients, four refused anti-HCV therapy, ribavirin was contraindicated in one and 19 initiated anti-HCV therapy. Median time between acute HCV diagnosis and initiation of study treatment was 14 weeks. Of the 14 patients who have achieved the post-treatment follow-up at 24 weeks, 10 had a sustained virological response (71%). Study treatment was well tolerated, with no change in CD4 cell count.
  
  
  CONCLUSIONS
  Early treatment of acute HCV infection with PegIFNalpha2a and ribavirin for 24 weeks yields a high sustained virological response rate in HIV-infected patients.
authors.affiliation: Department of Infectious and Tropical Diseases/INSERM U 720, CHU Pitié-Salpétrière, 47-83 Boulevard de l'Hôpital, 75651 Paris Cedex 13, France. stephanie.dominguez@psl.ap-hop-paris.fr
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Dominguez
authors.forename: Jade
authors.initials: J
authors.lastname: Ghosn
authors.forename: Marc-Antoine
authors.initials: MA
authors.lastname: Valantin
authors.forename: Aurélie
authors.initials: A
authors.lastname: Schruniger
authors.forename: Anne
authors.initials: A
authors.lastname: Simon
authors.forename: Philippe
authors.initials: P
authors.lastname: Bonnard
authors.forename: Eric
authors.initials: E
authors.lastname: Caumes
authors.forename: Gilles
authors.initials: G
authors.lastname: Pialoux
authors.forename: Yves
authors.initials: Y
authors.lastname: Benhamou
authors.forename: Vincent
authors.initials: V
authors.lastname: Thibault
authors.forename: Christine
authors.initials: C
authors.lastname: Katlama
mesh_terms: D000208:Acute Disease; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D015497:HIV-1 / Q000302:isolation & purification; D016174:Hepacivirus / Q000302:isolation & purification; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a